Findings based on comparison to glycopyrrolate-formoterol and tiotropium-olodaterol in patients newly prescribed LAMA-LABA inhalers<\/p>\n<\/h3>\n
By Lori Solomon HealthDay Reporter<\/b>
\n<\/b><\/p>\n
WEDNESDAY, Feb. 25, 2026 (HealthDay News) — Umeclidinium-vilanterol is associated with improved clinical outcomes compared with glycopyrrolate-formoterol and tiotropium-olodaterol in symptomatic patients with chronic obstructive pulmonary disease (COPD), according to a study published online Feb. 23 in JAMA Internal Medicine<\/em>.<\/p>\n Gerard T. Portela, Ph.D., from Brigham and Women\u2019s Hospital in Boston, and colleagues evaluated the comparative effectiveness and safety of once-daily umeclidinium-vilanterol dry powder inhalers, twice-daily glycopyrrolate-formoterol metered-dosed inhalers, and once-daily tiotropium-olodaterol soft mist inhalers. The analysis included claims data from 55,817 matched pairs (aged 40 years and older) newly treated with long-acting muscarinic antagonist\u2013long-acting \u03b22<\/sub>-agonist (LAMA-LABA) inhalers and continuously enrolled in a large commercial health insurance or Medicare Advantage plan during a 183-day baseline period.<\/p>\n The researchers found that umeclidinium-vilanterol was associated with a lower risk for a first moderate or severe COPD exacerbation versus glycopyrrolate-formoterol (hazard ratio [HR], 0.86; 95 percent confidence interval, 0.81 to 0.91; number needed to treat [NNT], 17). Umeclidinium-vilanterol also was associated with a lower risk compared with tiotropium-olodaterol (HR, 0.97; 95 percent confidence interval, 0.94 to 0.99; NNT, 100). Compared with glycopyrrolate-formoterol, tiotropium-olodaterol tended to be associated with a lower risk for a first moderate or severe COPD exacerbation (HR, 0.94; 95 percent confidence interval, 0.89 to 1.00). Across all three groups, the risks for first major adverse cardiovascular event, urinary tract infection, and pneumonia hospitalization were similar.<\/p>\n “Patients, prescribers, and health systems may consider once-daily umeclidinium-vilanterol dry powder inhalers over alternatives among new users of LAMA-LABA therapy,” the authors write.<\/p>\n Several authors disclosed ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n